AUROBINDO PHARMA
|
AUROBINDO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 60.02 | 54.16 | 32.90 | 45.20 | 91.05 |
| CEPS(Rs) | 88.38 | 80.06 | 54.14 | 64.41 | 109.05 |
| DPS(Rs) | - | 4.50 | 3.00 | 9.00 | 4.00 |
| Book NAV/Share(Rs) | 562.21 | 509.35 | 458.10 | 419.46 | 374.29 |
| Tax Rate(%) | 31.24 | 27.65 | 26.21 | 21.51 | 27.37 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.36 | 9.77 | 7.31 | 9.17 | 10.98 |
| EBIT Margin(%) | 8.69 | 7.81 | 5.41 | 7.16 | 15.27 |
| Pre Tax Margin(%) | 7.97 | 7.33 | 5.14 | 7.05 | 15.11 |
| PAT Margin (%) | 5.48 | 5.30 | 3.79 | 5.54 | 10.98 |
| Cash Profit Margin (%) | 8.08 | 7.85 | 6.24 | 7.89 | 13.15 |
| Performance Ratios | |||||
| ROA(%) | 7.54 | 7.63 | 5.29 | 7.90 | 17.16 |
| ROE(%) | 11.15 | 11.18 | 7.50 | 11.38 | 27.53 |
| ROCE(%) | 14.39 | 13.76 | 9.39 | 12.71 | 30.10 |
| Asset Turnover(x) | 1.38 | 1.44 | 1.40 | 1.43 | 1.56 |
| Sales/Fixed Asset(x) | 2.65 | 2.84 | 2.95 | 3.24 | 3.73 |
| Working Capital/Sales(x) | 5.09 | 5.17 | 5.10 | 4.84 | 5.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.35 | 0.34 | 0.31 | 0.27 |
| Receivable days | 30.33 | 28.34 | 30.42 | 28.69 | 29.37 |
| Inventory Days | 58.44 | 55.92 | 57.65 | 63.29 | 62.82 |
| Payable days | 135.14 | 133.88 | 117.74 | 108.60 | 111.03 |
| Valuation Parameters | |||||
| PER(x) | 19.32 | 20.12 | 15.75 | 14.80 | 9.68 |
| PCE(x) | 13.12 | 13.61 | 9.57 | 10.39 | 8.08 |
| Price/Book(x) | 2.06 | 2.14 | 1.13 | 1.59 | 2.36 |
| Yield(%) | - | 0.41 | 0.58 | 1.35 | 0.45 |
| EV/Net Sales(x) | 2.11 | 2.20 | 1.17 | 1.59 | 2.06 |
| EV/Core EBITDA(x) | 9.31 | 9.98 | 7.26 | 7.94 | 8.95 |
| EV/EBIT(x) | 12.14 | 13.68 | 10.58 | 10.92 | 6.90 |
| EV/CE(x) | 1.65 | 1.77 | 0.92 | 1.11 | 1.53 |
| M Cap / Sales | 2.12 | 2.20 | 1.22 | 1.67 | 2.08 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.39 | 16.68 | 5.97 | -5.32 | 7.26 |
| Core EBITDA Growth(%) | 12.57 | 59.64 | -14.83 | -17.62 | 13.02 |
| EBIT Growth(%) | 18.28 | 69.62 | -19.54 | -53.88 | 83.25 |
| PAT Growth(%) | 9.93 | 64.40 | -27.18 | -50.37 | 87.57 |
| EPS Growth(%) | 10.83 | 64.62 | -27.21 | -50.36 | 87.51 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.24 | 0.21 | 0.18 | 0.10 | 0.23 |
| Current Ratio(x) | 1.85 | 1.95 | 1.87 | 2.21 | 1.85 |
| Quick Ratio(x) | 1.13 | 1.14 | 1.13 | 1.29 | 1.00 |
| Interest Cover(x) | 12.08 | 16.12 | 19.60 | 70.34 | 99.58 |
| Total Debt/Mcap(x) | 0.12 | 0.10 | 0.16 | 0.06 | 0.10 |
Compare Financial Ratios of peers of AUROBINDO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AUROBINDO PHARMA | ₹75,771.2 Cr | 7.6% | 8% | 18.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹437,855.0 Cr | 3.6% | 7% | 15.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,550.0 Cr | 1.1% | 5.8% | 14.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,906.0 Cr | 1.9% | 12.3% | 49.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,632.0 Cr | 1.8% | 5.9% | 14.8% | Stock Analytics | |
| CIPLA | ₹107,427.0 Cr | 1.6% | 0.2% | -5.4% | Stock Analytics | |
AUROBINDO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AUROBINDO PHARMA | 7.6% |
8% |
18.6% |
| SENSEX | -2.9% |
-8% |
5.3% |
You may also like the below Video Courses
